AR051523A1 - Metodo para medir la resistencia o sensibilidad a docetaxel - Google Patents

Metodo para medir la resistencia o sensibilidad a docetaxel

Info

Publication number
AR051523A1
AR051523A1 ARP050105086A ARP050105086A AR051523A1 AR 051523 A1 AR051523 A1 AR 051523A1 AR P050105086 A ARP050105086 A AR P050105086A AR P050105086 A ARP050105086 A AR P050105086A AR 051523 A1 AR051523 A1 AR 051523A1
Authority
AR
Argentina
Prior art keywords
measuring
sensitivity
predict
concentrations
molecule
Prior art date
Application number
ARP050105086A
Other languages
English (en)
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of AR051523A1 publication Critical patent/AR051523A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Abstract

La presente se refiere a métodos nuevos y utiles que pronostican o controlan una respuesta del paciente a una molécula de la familia de los taxoides midiendo el aumento o disminucion de los marcadores genéticos específicos comparados con las referencia. La presente también proporciona kits que pronostican o controlan la respuesta del paciente a una molécula de la familia de los taxoides midiendo las concentraciones de ácido nucleico o de proteínas de determinados marcadores genéticos y comparando sus concentraciones con referencias o marcadores de referencia.
ARP050105086A 2004-12-08 2005-12-06 Metodo para medir la resistencia o sensibilidad a docetaxel AR051523A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63429804P 2004-12-08 2004-12-08

Publications (1)

Publication Number Publication Date
AR051523A1 true AR051523A1 (es) 2007-01-17

Family

ID=36512512

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105086A AR051523A1 (es) 2004-12-08 2005-12-06 Metodo para medir la resistencia o sensibilidad a docetaxel

Country Status (16)

Country Link
US (2) US20090226894A1 (es)
EP (10) EP2395110A1 (es)
JP (5) JP5139811B2 (es)
KR (10) KR101357033B1 (es)
CN (10) CN102605066A (es)
AR (1) AR051523A1 (es)
AU (1) AU2005314335C1 (es)
BR (1) BRPI0518884A2 (es)
CA (1) CA2589918A1 (es)
HK (2) HK1111441A1 (es)
IL (9) IL183718A (es)
MX (1) MX2007006867A (es)
RU (2) RU2403574C2 (es)
SG (2) SG194337A1 (es)
TW (10) TW201237179A (es)
WO (1) WO2006062811A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0606096D0 (en) * 2006-03-27 2006-05-03 Cbmm Sa Screening method
EP2468887A1 (en) * 2006-12-13 2012-06-27 Oncotherapy Science, Inc. TTK as tumor marker and therapeutic target for lung cancer
RS53165B (en) * 2007-03-14 2014-06-30 Bionsil S.R.L. BTK INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT EPITHELIC TUMORS
WO2009073478A2 (en) * 2007-11-30 2009-06-11 Applied Genomics, Inc. Tle3 as a marker for chemotherapy
EP2177630A1 (en) 2008-10-02 2010-04-21 Institut Gustave Roussy Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
DK2493466T3 (da) 2009-10-29 2021-04-26 Sanofi Mature Ip Hidtil ukendt antitumoral anvendelse af cabazitaxel
WO2011124669A1 (en) 2010-04-08 2011-10-13 Institut Gustave Roussy Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
JP2012005479A (ja) * 2010-05-26 2012-01-12 Japanese Foundation For Cancer Research 抗癌剤のスクリーニング方法
JP6302673B2 (ja) 2011-01-21 2018-03-28 バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのｂｕｂｒ１の使用
WO2013078145A1 (en) * 2011-11-21 2013-05-30 Taivex Therapeutics Corporation Biomarkers for cancers responsive to modulators of hec1 activity
US20140349878A1 (en) * 2011-11-28 2014-11-27 National Research Council Of Canada Paclitaxel response markers for cancer
CN102621325B (zh) * 2012-04-06 2014-11-12 上海蓝怡科技有限公司 用于检测血液中多西他赛浓度的试剂盒
CN105803053B (zh) * 2014-12-31 2021-03-16 上海吉凯基因科技有限公司 人rbm17基因的用途及其相关药物
CN105925611A (zh) * 2016-04-23 2016-09-07 同济大学苏州研究院 靶向hsp70基因rna干扰重组慢病毒载体及其构建方法
CN107447028A (zh) * 2017-09-13 2017-12-08 赵小刚 检测rb1基因i680t位点突变的试剂盒
CN108931633B (zh) * 2018-05-22 2021-08-27 郑州大学第一附属医院 胆囊癌诊断和预后判断标志物pim1
CN111944905B (zh) * 2020-08-20 2023-06-02 武汉凯德维斯医学检验实验室有限公司 人类基因组合及其在制备评估***新辅助化疗药物敏感性试剂盒中的应用
KR102596893B1 (ko) 2022-03-04 2023-11-01 우순 표적지 이송장치
KR102605155B1 (ko) 2022-03-04 2023-11-23 우순 다기능 표적 이송장치

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7807532A (nl) * 1978-07-13 1980-01-15 Akzo Nv Metaal-immunotest.
NL8000173A (nl) 1980-01-11 1981-08-03 Akzo Nv Toepassing van in water dispergeerbare, hydrofobe kleurstoffen als label in immunochemische testen.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4703017C1 (en) 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
JPS61231031A (ja) * 1985-04-08 1986-10-15 Agency Of Ind Science & Technol 二硫化炭素重合体の製造方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0280559B1 (en) 1987-02-27 1993-10-20 EASTMAN KODAK COMPANY (a New Jersey corporation) Agglutination immunoassay and kit for determination of a multivalent immune species using a buffered salt wash solution
DE3882058T2 (de) 1987-02-27 1994-01-13 Eastman Kodak Co Immunoreaktives Reagens, Verfahren zu seiner Herstellung und seine Verwendung zur Bestimmung einer immunoreaktiven Spezies.
US4857453A (en) * 1987-04-07 1989-08-15 Syntex (U.S.A.) Inc. Immunoassay device
JPH0746107B2 (ja) 1987-04-27 1995-05-17 ユニリーバー・ナームローゼ・ベンノートシヤープ 検定法
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5834298A (en) * 1995-08-01 1998-11-10 Sloan-Kettering Institute For Cancer Research Gene encoding the human homolog of MAD2
AU7828698A (en) * 1997-06-11 1998-12-30 Chiron Corporation Detection of loss of the wild-type (hu)bub1 gene
US6410312B1 (en) * 1997-12-19 2002-06-25 Chiron Corporation huBUB3 gene involved in human cancers
WO1999028459A1 (en) * 1997-11-27 1999-06-10 Chugai Research Institute For Molecular Medicine, Inc. Examination method, examination reagent and remedy for diseases caused by variation in lkb1 gene
CA2321458A1 (en) * 1998-02-18 1999-08-26 Hilmar Meek Warenius Treating cancer
ATE382148T1 (de) * 1998-09-24 2008-01-15 Promega Corp Antikörper für apoptosemarker und anwendungsverfahren
EP1140137A2 (en) * 1998-12-18 2001-10-10 Scios Inc. Method for detection and use of differentially expressed genes in disease states
AU2001245295A1 (en) * 2000-02-17 2001-08-27 Millennum Pharmaceuticals, Inc. Methods and compositions for the identification, assessment, prevention and therapy of human cancers
US20020051978A1 (en) * 2000-02-17 2002-05-02 Roth Frederick P. Methods and compositions for the identification, assessment, prevention and therapy of human cancers
CN101732717A (zh) * 2001-02-21 2010-06-16 诺华疫苗和诊断公司 用于诊断和作为癌症治疗靶标的ttk
US6783597B2 (en) * 2001-03-13 2004-08-31 3M Innovative Properties Company Filament recoating apparatus and method
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
DE10139283A1 (de) * 2001-08-09 2003-03-13 Epigenomics Ag Verfahren und Nukleinsäuren zur Analyse von Colon-Krebs
US20030235581A1 (en) * 2002-06-20 2003-12-25 George Pieczenik Ligands for Reproductive Science
SI1546182T1 (sl) * 2002-09-11 2011-04-29 Genentech Inc Sestavki in postopki za diagnozo in zdravljenje tumorja
US20040214203A1 (en) * 2002-12-12 2004-10-28 Oncotech, Inc. Genes related to sensitivity and resistance to chemotherapeutic drug treatment
DE10260264A1 (de) * 2002-12-20 2004-07-01 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verfahren und Zelllinie zur Identifizierung proliferationshemmender, anti-inflammatorischer oder proliferationsfördender Wirkstoffe
EP1661991A4 (en) * 2003-08-24 2007-10-10 Univ Nihon WITH HEPATOCELLULAR CARCINOMA ASSOCIATED GEN
US20050136177A1 (en) * 2003-08-25 2005-06-23 Anthony Hesse Method for coloring landscaping materials using foamable dry colorant
DK2163650T3 (en) * 2004-04-09 2015-11-02 Genomic Health Inc Genekspressionsmarkører for prediction of response to chemotherapy
JP2006014722A (ja) * 2004-06-02 2006-01-19 Keio Gijuku 遺伝子マーカー及びその利用
GB0426393D0 (en) * 2004-12-01 2005-01-05 Cancer Rec Tech Ltd Materials and methods relating to modulators of spindle checkpoint kinases
US7957910B2 (en) * 2005-01-31 2011-06-07 Sysmex Corporation Method for predicting effectiveness of chemotherapy
EP2177630A1 (en) * 2008-10-02 2010-04-21 Institut Gustave Roussy Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family

Also Published As

Publication number Publication date
KR20130099246A (ko) 2013-09-05
IL210298A0 (en) 2011-03-31
CN102618642A (zh) 2012-08-01
IL221772A (en) 2014-06-30
KR20130105762A (ko) 2013-09-25
KR101323574B1 (ko) 2013-10-30
JP5531002B2 (ja) 2014-06-25
CN102747140A (zh) 2012-10-24
KR101357032B1 (ko) 2014-02-03
MX2007006867A (es) 2007-08-06
KR101357033B1 (ko) 2014-02-03
TW201237175A (en) 2012-09-16
JP2012100665A (ja) 2012-05-31
EP2395108A1 (en) 2011-12-14
EP2395105A1 (en) 2011-12-14
KR20130105758A (ko) 2013-09-25
HK1153786A1 (en) 2012-04-05
RU2403574C2 (ru) 2010-11-10
AU2005314335B2 (en) 2012-02-02
CN101974619A (zh) 2011-02-16
IL205702A0 (en) 2011-07-31
US20090226894A1 (en) 2009-09-10
KR101357040B1 (ko) 2014-02-03
CN102618642B (zh) 2014-12-31
JP5531000B2 (ja) 2014-06-25
IL210298A (en) 2012-12-31
KR20130004381A (ko) 2013-01-09
JP5530999B2 (ja) 2014-06-25
TW201237177A (en) 2012-09-16
EP2395107A1 (en) 2011-12-14
KR20130105760A (ko) 2013-09-25
TW201241178A (en) 2012-10-16
EP1831398B1 (en) 2014-10-29
EP2395103A1 (en) 2011-12-14
EP2395110A1 (en) 2011-12-14
WO2006062811A2 (en) 2006-06-15
EP2395109A1 (en) 2011-12-14
KR101347107B1 (ko) 2014-01-02
CN101974619B (zh) 2012-11-21
EP2395102A1 (en) 2011-12-14
CN101072883A (zh) 2007-11-14
IL183718A0 (en) 2007-09-20
SG194337A1 (en) 2013-11-29
CA2589918A1 (en) 2006-06-15
EP1831398A2 (en) 2007-09-12
CN102618641B (zh) 2014-08-13
AU2005314335C1 (en) 2012-08-16
CN102747141A (zh) 2012-10-24
CN102634574A (zh) 2012-08-15
KR101357039B1 (ko) 2014-02-03
EP2395104A1 (en) 2011-12-14
IL205635A (en) 2013-02-28
KR20130113527A (ko) 2013-10-15
JP2012115267A (ja) 2012-06-21
BRPI0518884A2 (pt) 2008-12-30
KR20130113526A (ko) 2013-10-15
CN102747142A (zh) 2012-10-24
IL225469A0 (en) 2013-06-27
KR20130105761A (ko) 2013-09-25
SG156625A1 (en) 2009-11-26
IL221772A0 (en) 2012-10-31
KR101347106B1 (ko) 2014-01-02
KR101357035B1 (ko) 2014-02-03
JP2012100666A (ja) 2012-05-31
CN102605066A (zh) 2012-07-25
KR20130105759A (ko) 2013-09-25
CN101072883B (zh) 2012-05-23
RU2007125722A (ru) 2009-01-20
TW200636076A (en) 2006-10-16
KR20070085986A (ko) 2007-08-27
TW201237174A (en) 2012-09-16
EP2395106A1 (en) 2011-12-14
RU2010122759A (ru) 2011-12-10
CN102605067A (zh) 2012-07-25
JP2008522615A (ja) 2008-07-03
JP5139811B2 (ja) 2013-02-06
TW201241177A (en) 2012-10-16
IL183718A (en) 2013-04-30
AU2005314335A1 (en) 2006-06-15
WO2006062811A3 (en) 2006-09-14
TW201237179A (en) 2012-09-16
IL210299A (en) 2012-12-31
IL205636A (en) 2012-08-30
CN102634574B (zh) 2014-11-12
US20130252837A1 (en) 2013-09-26
TW201237178A (en) 2012-09-16
TW201237176A (en) 2012-09-16
HK1111441A1 (en) 2008-08-08
KR101357037B1 (ko) 2014-02-03
TW201241176A (en) 2012-10-16
IL210299A0 (en) 2011-03-31
CN102618641A (zh) 2012-08-01
KR101357038B1 (ko) 2014-02-03
IL225468A0 (en) 2013-06-27
JP2012120532A (ja) 2012-06-28
JP5531001B2 (ja) 2014-06-25

Similar Documents

Publication Publication Date Title
AR051523A1 (es) Metodo para medir la resistencia o sensibilidad a docetaxel
AR109260A2 (es) Secuencias de nucleótidos que codifican proteínas insecticidas
AR064509A1 (es) Promotores inducibles por el gen peroxidasa del nematodo y metodos de uso
AR053272A1 (es) Determinacion de responsivos a la quimioterapia
CY1116279T1 (el) Η χρηση των ανθρωπινων κυτταρων προελευσης μυελογενους λευχαιμιας για την εκφραση αντισωματων
ATE412905T1 (de) Diagnoseverfahren für lebersteatose unter verwendung biochemischer marker
AR057323A1 (es) Metodo para la prediccion de la respuesta a un tratamiento
DE602007010360D1 (de) Verfahren zur diagnose und/oder prognose von blasenkrebs
BR112018074853A2 (pt) métodos para detectar a presença de pelo menos um genogrupo de norovírus em uma amostra de fezes e para selecionar um paciente que sofre de gastroenterite aguda, e, kit
BR112017020582A2 (pt) composições e métodos para a detecção de um contaminante biológico
CO6280567A2 (es) Establecimiento de un anticuerpo monoclonal para detector de proteinas pag en la circulacion
JP2014160088A5 (es)
BR112016019740A2 (pt) monitoramento do estado de inflamação
BR112018069316A2 (pt) métodos para detectar presença de pelo menos uma espécie de bordetella patogênica e selecionar um paciente que exibe sintomas semelhantes à coqueluche, e, kit para detectar presença de pelo menos uma espécie de bordetella patogênica.
BR112012005670A2 (pt) ''método para a identificação de um paciente com câncer que pode se beneficiar com a terapia antiagiogênica, método para a predição da responsividade de um paciente com câncer à terapia antiangiogênica, uso de um anticorpo anto- vegf para melhorar o efeito do tratamento de um paciente sofrendo de câncer, método ou uso, kit útil para realizar o método, uso de uma proteína ou usom kit útil para realizar o método, uso de uma proteína ou oligonucleotídeo ou matriz de polinecleotídeo para determinar o nível de expressão de bfgf em um método e kit ou uso
BRPI0415277A (pt) célula, vetor, método para produzir proteìna gama-carboxilada, proteìna gama-carboxilada isolada, uso da mesma, método para produzir uma composição farmacêutica, composição farmacêutica, método para produzir fator x de humano gama-carboxilado, uso de fator x isolado, método para produzir protrombina de humano gama-carboxilada, uso de protrombina isolada, e, método para promover coagulação aumentada ou diminuìda em um indivìduo
DE602006015702D1 (de) Unterscheidung zwischen baktiereller meningitis und viraler meningitis
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
AR058510A1 (es) Procedimiento de diagnostico de enfermedades hepaticas y de muestreo de moleculas para el tratamiento de estas enfermedades
AR070933A1 (es) Ensayo basado en fluorescencia para detectar compuestos que modulan el modo inverso del intercambiador de sodio /calcio (ncx)
AR059326A1 (es) Resistencia a la mastitis
ATE555384T1 (de) Verfahren zum testen der reaktion von zellen auf die einwirkung von therapeutika
AR087641A1 (es) Metodo para predecir el beneficio clinico del tratamiento de los trastornos del desarrollo neurologico, neurologicos o neuropsiquiatricos
BRPI0418022A (pt) biomarcadores para sensibilidade de doenças proliferativas a inibidores de mtor
EA201200925A1 (ru) Способ определения функционального состояния биологической ткани и применение этого способа для определения ее жизнеспособности и/или степени некротизации

Legal Events

Date Code Title Description
FB Suspension of granting procedure